It seems to me that we're in a waiting mode -- waiting for news about Servier's trial, waiting for news about the MJFF trial, waiting for funding for the ADHD Phase IIb. I'm sure I'm not the only one who thinks that management's silence means that nothing is happening.
But if Servier's Phase I shows promising results, maybe some other company will be intersested in a newer high impact. If the MJFF research shows promise, maybe something will develop there. So I guess we just wait -- for the ASM, for a presentation, for a pr.
I'd take $.25/sh. for my lot. Hey, that's a double from here.